ATE545657T1 - Tgf-beta antikörper - Google Patents

Tgf-beta antikörper

Info

Publication number: ATE545657T1
Authority: AT; Austria
Prior art keywords: tgf; beta antibodies; antibodies; mammal; antigen
Prior art date: 2005-12-23

Application number

AT06840328T

Other languages

English (en)

Inventor

Bryan Jones

James Pancook

Scott Rowlinson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-23

Filing date

2006-12-20

Publication date

2012-03-15

2006-12-20 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE545657T1 publication Critical patent/ATE545657T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT06840328T 2005-12-23 2006-12-20 Tgf-beta antikörper ATE545657T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US75395605P	2005-12-23	2005-12-23
PCT/US2006/062397 WO2007076391A1 (en)	2005-12-23	2006-12-20	Tgf-beta binding compositions

Publications (1)

Publication Number	Publication Date
ATE545657T1 true ATE545657T1 (de)	2012-03-15

Family

ID=37898733

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06840328T ATE545657T1 (de)	2005-12-23	2006-12-20	Tgf-beta antikörper

Country Status (10)

Country	Link
US (3)	US7494651B2 (de)
EP (1)	EP1966243B1 (de)
JP (1)	JP2009521496A (de)
CN (1)	CN101346394B (de)
AT (1)	ATE545657T1 (de)
AU (1)	AU2006330542B2 (de)
BR (1)	BRPI0620240A2 (de)
CA (1)	CA2632799A1 (de)
ES (1)	ES2379194T3 (de)
WO (1)	WO2007076391A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1740615B1 (de) *	2004-03-31	2014-11-05	Genentech, Inc.	Humanisierte anti-tgf-beta-antikörper
US7494651B2 (en) *	2005-12-23	2009-02-24	Eli Lilly And Company	TGF-β binding antibodies
US8350006B2 (en) *	2008-10-24	2013-01-08	Mead Johnson Nutrition Company	Methods for determining the bioactivity of TGF-β in a composition
EP2894226B1 (de) *	2009-01-08	2021-04-14	Bio-Rad Laboratories, Inc.	Verfahren und zusammensetzung zur verbesserung der wirksamkeit bei einer nukleinsäureverstärkungsreaktion
WO2010124276A2 (en) *	2009-04-24	2010-10-28	Vanderbilt Universtiy	Anti-tgf-beta induction of bone cell function and bone growth
CN103732623B (zh)	2011-06-03	2017-09-29	佐马技术有限公司	对TGF‑β具有特异性的抗体
WO2013134365A1 (en)	2012-03-08	2013-09-12	Ludwig Institute For Cancer Research Ltd	TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
MX2014010839A (es)	2012-03-08	2016-07-06	Selig Sealing Products Inc	Sello de recipiente con componente de seguridad protegido y lengüeta de remocion.
HUE046702T2 (hu)	2013-03-20	2020-03-30	Genzyme Corp	Eljárások üvegcsontbetegség kezelésére
WO2016024628A1 (ja) *	2014-08-14	2016-02-18	学校法人東京医科大学	樹状細胞の抗癌免疫賦活能の促進方法およびその用途
GB2557389B (en)	2015-01-14	2020-12-23	Brigham & Womens Hospital Inc	Treatment of cancer with anti-lap monoclonal antibodies
TWI726870B (zh)	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN116327915A (zh)	2015-04-03	2023-06-27	佐马技术有限公司	使用TGF-β抑制剂和PD-1抑制剂治疗癌症
US10723793B2 (en)	2015-06-12	2020-07-28	Ludwig Institute For Cancer Research, Ltd.	TGF-β3 specific antibodies and methods and uses thereof
MX2018014047A (es)	2016-05-17	2019-06-20	Genentech Inc	Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
GB201610044D0 (en)	2016-06-08	2016-07-20	Ucb Biopharma Sprl	Antibodies
MX2020004567A (es)	2017-11-06	2020-08-13	Genentech Inc	Metodos diagnosticos y terapeuticos para el cancer.
CN112638401B (zh)	2018-06-29	2024-11-19	璟尚生物制药公司	抗肿瘤拮抗剂
AU2019375036A1 (en)	2018-11-05	2021-06-03	Centre Hospitalier Universitaire Vaudois	Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
CN113613726A (zh)	2018-11-05	2021-11-05	路德维格癌症研究所有限公司	人源化和变体TGF-β3特异性抗体及其方法和用途
WO2020263312A1 (en)	2019-06-28	2020-12-30	Gensun Biopharma, Inc.	ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021021991A1 (en)	2019-08-01	2021-02-04	Vaccinex,Inc.	Combined inhibition of semaphorin-4d and tgfb and compositions therefor
JP2023514324A (ja)	2020-02-19	2023-04-05	ナミセラピューティクス，インコーポレイテッド	がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
CN113563473A (zh)	2020-04-29	2021-10-29	三生国健药业（上海）股份有限公司	四价双特异性抗体、其制备方法和用途
WO2022109443A1 (en) *	2020-11-23	2022-05-27	The Regents Of The University Of Michigan	Single-chain antibody against flavivirus ns1 protein
EP4251645A1 (de)	2020-11-25	2023-10-04	Catamaran Bio, Inc.	Mit signalmodulatoren manipulierte zelluläre therapeutika und verfahren zur verwendung davon
CN112940119B (zh) *	2021-04-26	2022-05-20	北京芳渟阳生生物科技有限公司	一种单克隆抗体及其与间充质干细胞外泌体的联合应用
CN115707716A (zh) *	2021-08-18	2023-02-21	丹生医药技术(上海)有限公司	一种TGF-β/VEGF双功能抗体融合蛋白
WO2023080900A1 (en)	2021-11-05	2023-05-11	Genentech, Inc.	Methods and compositions for classifying and treating kidney cancer
CN119213034A (zh)	2022-05-17	2024-12-27	苏州创胜医药集团有限公司	双功能蛋白质及其制剂和用途
WO2024077095A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating lung cancer
WO2024149237A1 (zh) *	2023-01-09	2024-07-18	北京拓界生物医药科技有限公司	TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO2005010049A2 (en) *	2003-07-09	2005-02-03	Eli Lilly And Company	Tgf-beta1 ligands
EP1740615B1 (de) *	2004-03-31	2014-11-05	Genentech, Inc.	Humanisierte anti-tgf-beta-antikörper
US7494651B2 (en) *	2005-12-23	2009-02-24	Eli Lilly And Company	TGF-β binding antibodies

2006
- 2006-12-20 US US12/096,383 patent/US7494651B2/en not_active Expired - Fee Related
- 2006-12-20 CA CA002632799A patent/CA2632799A1/en not_active Abandoned
- 2006-12-20 AT AT06840328T patent/ATE545657T1/de active
- 2006-12-20 CN CN2006800485519A patent/CN101346394B/zh not_active Expired - Fee Related
- 2006-12-20 JP JP2008547744A patent/JP2009521496A/ja not_active Ceased
- 2006-12-20 AU AU2006330542A patent/AU2006330542B2/en not_active Ceased
- 2006-12-20 WO PCT/US2006/062397 patent/WO2007076391A1/en active Application Filing
- 2006-12-20 BR BRPI0620240-3A patent/BRPI0620240A2/pt not_active IP Right Cessation
- 2006-12-20 ES ES06840328T patent/ES2379194T3/es active Active
- 2006-12-20 EP EP06840328A patent/EP1966243B1/de not_active Not-in-force
2009
- 2009-02-06 US US12/366,664 patent/US20090155285A1/en not_active Abandoned
2010
- 2010-01-26 US US12/693,722 patent/US7927593B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100136021A1 (en)	2010-06-03
US20080292638A1 (en)	2008-11-27
US7927593B2 (en)	2011-04-19
WO2007076391A1 (en)	2007-07-05
EP1966243B1 (de)	2012-02-15
BRPI0620240A2 (pt)	2011-11-08
JP2009521496A (ja)	2009-06-04
EP1966243A1 (de)	2008-09-10
CN101346394A (zh)	2009-01-14
ES2379194T3 (es)	2012-04-23
US7494651B2 (en)	2009-02-24
CA2632799A1 (en)	2007-07-05
CN101346394B (zh)	2012-07-25
US20090155285A1 (en)	2009-06-18
AU2006330542A1 (en)	2007-07-05
WO2007076391A9 (en)	2008-08-28
AU2006330542B2 (en)	2012-05-24

Publication	Publication Date	Title
ATE545657T1 (de)	2012-03-15	Tgf-beta antikörper
NO20082905L (no)	2008-09-03	Anti-IL-17 antistoff
ZA200707258B (en)	2008-06-25	Novel anti-PLGF antibody
TNSN08255A1 (en)	2009-10-30	Anti-mn antibodies and methods of using same
EA200802168A1 (ru)	2009-06-30	Гуманизированное антитело к с-kit
NO2017032I1 (no)	2017-07-07	bezlotoksumab
TW200714290A (en)	2007-04-16	Anti-M-CSF antibody compositions having reduced levels of endotoxin
ATE526987T1 (de)	2011-10-15	Dr5-antikörper und deren verwendung
MXPA06014510A (es)	2007-09-19	Composiciones y metodos para tratar trastornos inflamatorios.
UA92504C2 (en)	2010-11-10	Anti-myostatin monoclonal antibody
DK2135881T3 (da)	2011-12-05	Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
WO2006118772A3 (en)	2007-05-31	Fcrn antibodies and uses thereof
EA201390146A1 (ru)	2013-12-30	Антитела к матриксной металлопротеиназе 9
DE602006013029D1 (de)	2010-04-29	Anti-egfr-antikörper
DK1706424T3 (da)	2009-11-02	FC-region varianter
EA201491575A1 (ru)	2015-01-30	Антитела к матриксной металлопротеиназе 9
WO2008085878A3 (en)	2009-02-26	High affinity antibodies that neutralize staphylcoccus enterotoxin b
EA200700876A1 (ru)	2007-10-26	Агенты, специфически связывающие ангиопоэтин-2
HK1154904A1 (zh)	2012-05-04	天然抗體及其抑制劑
UA94211C2 (ru)	2011-04-26	Выделенное полностью человеческое моноклональное cd3 антитело
WO2007038407A3 (en)	2007-06-14	Compositions and methods for treating nervous system disorders
TW200738236A (en)	2007-10-16	Certain chemical entities, compositions, and methods
UA98100C2 (ru)	2012-04-25	Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
UA96426C2 (ru)	2011-11-10	Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
UA94245C2 (en)	2011-04-26	Anti-il-17 antibodies